International Stem Cell Corp. continues its pursuit of advancing regenerative medicine through its use and research of stem cells in the white hot biotechnology space. ISCO uses parthenogenesis, a stem cell technology that makes use of unfertilized eggs to address … Continue reading →

International Stem Cell Corp., a California-based biotech company developing novel stem cell-based therapies and biomedical products, this morning said it will make an oral presentation on the comprehensive results of its preclinical development of human parthenogenetic neural stem cells (hPNSCs) … Continue reading →

The International Stem Cell Corporation, a biotechnology company, continues its developmental research of using stem cells to advance regenerative medicine. The company uses stem cell technology called parthenogenesis that uses unfertilized eggs to address immune system rejection. These eggs have … Continue reading →

International Stem Cell Corp., a biotechnology company developing novel stem cell-based therapies, announced that its scientific team has developed a robust innovative technology to generate functional articular cartilage from the patient’s own skin or adipose tissue to treat osteoarthritis. ISCO … Continue reading →

Stem cell technology’s real untilled and still extremely fertile soil is the therapeutics market, where injected cells could help repair damaged tissue systems and thus effectively treat many conditions, including degenerative ones, for which the current standard of care is … Continue reading →

Today before the opening bell, International Stem Cell Corp. announced that Mahnaz Ebrahimi will be taking over as the new chief financial officer, effective September 14, 2015. The prior CFO, Jay Novak, ended his employment in May. Ms. Ebrahimi is … Continue reading →

The promise of stem cell tissue transplantation is particularly exciting for conditions such as Parkinson’s disease, an incurable and progressive disorder of the nervous system characterized by a gradual at first, and then increasingly severe impairment of various motor control … Continue reading →

Today before the opening bell, International Stem Cell Corp. announced that it has entered into the second phase of the existing Research Agreement with Rohto Pharmaceutical Co., Ltd. (“Rohto”), a global Japanese pharmaceutical company recognized as the second-largest consumer health … Continue reading →

International Stem Cell (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, this morning announced that company board member and Chief Scientific Officer Ruslan Semechkin, PhD, will present at the upcoming Rodman and Renshaw 17th … Continue reading →

On the cusp of milestone TGA (Therapeutic Goods Administration) authorization in Australia to start clinical trials in its breakthrough Parkinson’s disease (PD) treatment using human parthenogenetic neural stem cells (hpNSCs), International Stem Cell Corp. (OTCQB: ISCO) was proud to show … Continue reading →